CAS No.16595-80-5,Levamisole hydrochloride Suppliers,MSDS download

Products Categories

Pharmaceutical (570)
Organic Chemicals (73)
Others (18)
Reagent (11)
Plant Extract (5)
Food Additives (3)
(2)
Materials (2)
Catalyst and Auxiliary (1)

Basic Information

Molecular Structure:
CAS No.:	16595-80-5
Name:	Levamisole hydrochloride
Article Data:	5

Formula:	C₁₁H₁₂N₂S^.HCl
Molecular Weight:	240.757
Synonyms:	Imidazo[2,1-b]thiazole, 2,3,5, 6-tetrahydro-6-phenyl-, monohydrochloride, (-)-;Decaris;Prestwick_294;Tramisole;2,3,5,6-Tetrahydro-6-phenyl-imidazo[2,1-b]thiazole, (S)-;L(-)-Levamisole;Niratic-PurOn hydrochloride;(7S)-7-phenyl-4-thia-1,6-diazabicyclo[3.3.0]oct-5-ene hydrochloride;Tramisol;Ergamisol (TN);L-Tetramisole hydrochloride;Niratic hydrochloride;L-Narpenol;Imidazo[2, 1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, L-(-)-;Ergamisol;
EINECS:	240-654-6
Melting Point:	266-267 ºC
Boiling Point:	344.4 ºC at 760 mmHg
Flash Point:	162.1 ºC
Solubility:	210 g/L (20 ºC) in water
Appearance:	white to almost white crystalline powder
Hazard Symbols:	T,Xn
Risk Codes:	25-20/21/22
Safety:	36/37/39-45-28A-36
Transport Information:	UN 2811 6.1/PG 3
PSA:	40.90000
LogP:	2.32160

Synthetic route

levamisole.L-N-[(4-methoxyphenyl)sulfonyl]glutamic acid (salt): levamisole.L-N-[(4-methoxyphenyl)sulfonyl]glutamic acid (salt)

: 108-88-3
toluene

levamisole hydrochloride: 16595-80-5
levamisole hydrochloride

Conditions

Conditions	Yield
With sodium hydroxide In water	94.2%

: 14769-73-4
Levamisole

: 16595-80-5
levamisole hydrochloride

Conditions

Conditions	Yield
Stage #1: Levamisole With sodium metabisulfite; pyrographite In isopropyl alcohol for 0.5h; Stage #2: With hydrogenchloride pH=4 - 5; Time;	92.1%

: 5036-02-2
Tetramisole

A: 16595-80-5
levamisole hydrochloride

B: 16595-76-9
(+)-Tetramisole hydrochloride

Conditions

Conditions	Yield
With hydrogenchloride In isopropyl alcohol; toluene Title compound not separated from byproducts;	A 16 g B n/a

: 16595-80-5
levamisole hydrochloride

: 14769-73-4
Levamisole

Conditions

Conditions	Yield
With sodium hydroxide In diethyl ether; water Inert atmosphere;	98%
With sodium hydroxide In water pH=12;	98.32%
With sodium hydroxide In diethyl ether; water at 20℃; for 0.166667h;	91%

: 15243-33-1
dodecacarbonyl-triangulo-triruthenium

: 16595-80-5
levamisole hydrochloride

: Ru3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

: Ru3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

Conditions

Conditions	Yield
In tetrahydrofuran (under N2, Schlenk); mixt. of Ru3(CO)12 and ligand stirred in THF at reflux temp. for 40 min, cooled to room temp., left aside for 24 h; filtered, concd., hexane added, ppt. washed with hexane, dried in vacuo,recrystd. from CH2Cl2-hexane; elem. anal.;	A n/a B 9%

...Expand

: 103257-53-0
Ru3(CH3CN)2(CO)10

: 16595-80-5
levamisole hydrochloride

: Ru3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

: Ru3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

Conditions

Conditions	Yield
In dichloromethane (under N2, Schlenk); ligand added to CH2Cl2 soln. of Ru3(CO)10(MeCN)2, 2min; TLC on silica gel, heated to reflux for 1 h;

...Expand

: 61817-93-4, 146143-79-5, 871132-66-0
Os3(CO)10(CH3CN)2

: 16595-80-5
levamisole hydrochloride

: Os3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

: Os3(μ-Cl)(μ-1-ethyelenethiolate-3-H-4-(S)-phenylimidazolin-2-ylidene)(CO)9

Conditions

Conditions	Yield
In tetrahydrofuran (under N2, Schlenk); ligand added to THF soln. of Os3(CO)10(MeCN)2, stirred at reflux for 40 min; solvent removed under reduced pressure, residue dissolved in CH2Cl2, silica gel chromy. with hexane:CH2Cl2 4:1, and hexane:CH2Cl2 1:1; elem. anal.;

...Expand

: trifluorobenzylideneacetone

: 16595-80-5
levamisole hydrochloride

: C18H13F3O2

: C18H13F3O2

Conditions

Conditions	Yield
Stage #1: trifluorobenzylideneacetone; levamisole hydrochloride With pivaloyl chloride; N-ethyl-N,N-diisopropylamine Stage #2: With 3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine In dichloromethane at 20℃; for 16h;	A n/a B n/a

...Expand

: trifluorobenzylideneacetone

: 16595-80-5
levamisole hydrochloride

: C18H13F3O2

: C18H13F3O2

: C18H13F3O2

Conditions

Conditions	Yield
Stage #1: trifluorobenzylideneacetone; levamisole hydrochloride With pivaloyl chloride; N-ethyl-N,N-diisopropylamine Stage #2: With (2S,3R)-3-isopropyl-2-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine In dichloromethane at -78℃; for 16h; enantioselective reaction;	A n/a B n/a C n/a

...Expand

: 16595-80-5
levamisole hydrochloride

: 32339-82-5
levamisole citrate

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1: sodium hydroxide / water / pH 12 2: ethanol View Scheme

Raw Materials

5036-02-2

Downstream Products

14769-73-4

Total:251 Page 1 of 7 1 2 3 4 5 6 …7 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 16595-80-5

Chemistry

IUPAC Name: (6S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole hydrochloride
Molecular Formula: C₁₁H₁₂N₂S^.HCl
Molecular Weight: 240.75 g/mol
SMILES: c1([C@H]2CN3CCSC3=N2)ccccc1.Cl
InChI: InChI=1/C11H12N2S.ClH/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10;/h1-5,10H,6-8H2;1H/t10-;/m1./s1
EINECS: 240-654-6
Classification Code: Biological response modifier; Drug / Therapeutic Agent; Human Data; Immunomodulator; Mutation data; Reproductive Effect
Product Categories: API; Asymmetric Synthesis; Synthetic Organic Chemistry; Antibiotic Explorer; Veterinaries; Protein Phosphatase
Melting Point: 266-267 °C(lit.)
alpha: -128 °(c=5, H₂O)
refractive index: -126 ° (C=1, H₂O)
storage temperature: 0-6 °C
Water Solubility: 210 g/L (20 °C)
Flash Point: 162.1 °C
Enthalpy of Vaporization: 58.83 kJ/mol
Boiling Point: 344.4 °C at 760 mmHg
Vapour Pressure of Levamisole hydrochloride (CAS NO.16595-80-5): 6.61E-05 mmHg at 25 °C

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
frog	LD50	parenteral	363mg/kg (363mg/kg)		Archives Internationales de Pharmacodynamie et de Therapie. Vol. 289, Pg. 278, 1987.
mouse	LD50	intramuscular	121mg/kg (121mg/kg)		Fortschritte der Medizin. Vol. 94, Pg. 793, 1976.
mouse	LD50	intraperitoneal	34mg/kg (34mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
mouse	LD50	intravenous	18mg/kg (18mg/kg)	BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
mouse	LD50	oral	223mg/kg (223mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
mouse	LD50	subcutaneous	52mg/kg (52mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
rat	LD50	intraperitoneal	42mg/kg (42mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
rat	LD50	intravenous	26mg/kg (26mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
rat	LD50	oral	180mg/kg (180mg/kg)		Archives of Toxicology. Vol. 54, Pg. 275, 1983.
rat	LD50	subcutaneous	80mg/kg (80mg/kg)	BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982.
women	TDLo	oral	180mg/kg/36D (180mg/kg)	BLOOD: THROMBOCYTOPENIA	British Medical Journal. Vol. 2, Pg. 555, 1977.

Safety Profile

Poison by ingestion, intraperitoneal, subcutaneous, intravenous, and intramuscular routes. An experimental teratogen. Human systemic effects by ingestion: thrombocytopenia. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NO_x, SO_x, and HCl.
Hazard Codes: Toxic T, Harmful Xn
Risk Statements: 25-20/21/22
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
R25 :Toxic if swallowed.
Safety Statements: 36/37/39-45-28A-36
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S28:After contact with skin, wash immediately with plenty of soap-suds.
S36:Wear suitable protective clothing.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: NJ5960000
HazardClass: 6.1(b)
PackingGroup of Levamisole hydrochloride (CAS NO.16595-80-5): III

Specification

Levamisole hydrochloride (CAS NO.16595-80-5), its Synonyms are (-)-2,3,5,6-Tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride ; Ascaridil ; Citarin L ; Decaris ; Ergamisol ' Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (S)- ; Levamisole HCl ; Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)- (8CI) . It is white to almost white crystalline powder.